A study of the safety and effectiveness of benralizumab to treat patients with severe uncontrolled asthma. - ANDHI

Study identifier:D3250C00045

ClinicalTrials.gov identifier:NCT03170271

EudraCT identifier:2017-001040-35

CTIS identifier:N/A

Study Complete

Official Title

A Multicenter, Randomized, Double-blind, Parallel Group, Placebo controlled, Phase 3b Study to Evaluate the Safety and Efficacy of Benralizumab 30 mg sc in Patients with Severe Asthma Uncontrolled on Standard of Care Treatment

Medical condition

asthma

Phase

Phase 3

Healthy volunteers

No

Study drug

Benralizumab (Medi-563), Placebo

Sex

All

Actual Enrollment

660

Study type

Interventional

Age

18 Years - 75 Years

Date

Study Start Date: 07 Jul 2017
Primary Completion Date: 25 Sept 2019
Study Completion Date: 21 Oct 2020

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Oct 2021 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria